Strata Skin Sciences Reports Q1 2025 Financial Results

Strata Skin Sciences ( (SSKN) ) just unveiled an announcement.

On May 14, 2025, STRATA Skin Sciences announced its financial results for the first quarter ending March 31, 2025. The company reported a revenue increase of 1% to $6.8 million, with international growth offsetting domestic declines. Gross margins improved significantly by 790 basis points, and operating expenses decreased by 5%. Despite a net loss of $2.4 million, the company showed progress with improved adjusted EBITDA and a strategic focus on international markets, which now account for 36% of total revenue.

The most recent analyst rating on (SSKN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Strata Skin Sciences stock, see the SSKN Stock Forecast page.

Spark’s Take on SSKN Stock

According to Spark, TipRanks’ AI Analyst, SSKN is a Neutral.

Strata Skin Sciences exhibits notable financial challenges with persistent losses and declining equity, contributing to a low financial performance score. Technical analysis suggests a bearish trend, while valuation metrics indicate significant concerns due to negative earnings. Despite these challenges, the company shows positive developments in its earnings call and recent corporate events, which include strategic international growth and product advancements. These factors provide some support for the stock’s overall outlook.

To see Spark’s full report on SSKN stock, click here.

More about Strata Skin Sciences

STRATA Skin Sciences, Inc. is a medical technology company focused on developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions.

Average Trading Volume: 5,407

Technical Sentiment Signal: Sell

Current Market Cap: $10.64M

Learn more about SSKN stock on TipRanks’ Stock Analysis page.